Co-Diagnostics and Synbiotics announced CoSara Diagnostics, a Joint Venture for manufacturing, has broken ground for its manufacturing facility in India.
Co-Diagnostics and Synbiotics incorporated the CoSara entity in India in July 2017. Since that time, CoSara has secured permits and approved building plans necessary to begin construction of a facility that will manufacture Co-Diagnostics products according to internationally recognized Good Manufacturing Practice (GMP) standards. GMP-produced diagnostics are required by many laboratories and hospitals to ensure that the products are manufactured in facilities with proper design and control processes in place. The facility is expected to be completed in April 2018, at which time CoSara will have the exclusive Indian manufacturing rights for Co-Diagnostics products.
“Manufacturing our products according to GMP standards underscores our commitment to quality in all stages of Co-Diagnostics products’ design and production cycles,” Dwight Egan, Co-Diagnostics CEO, said. “It also allows CoSara access to the institutions that insist on the high-level standards that accompany GMP-produced products, both in India and worldwide as the manufacturing facility grows to accommodate global demand for innovative and cost-conscious products built on Co-Diagnostics’ technology platform.”